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Abstract 
Potential drug-drug interactions (pDDIs) are a serious and frequent 
health issue, leading to often preventable and predictable adverse drug 
reactions and other negative outcomes. The objective of this study was to 
assess the frequency of potential drug-drug interactions and characterize 
them in patients hospitalized in an Infectious Diseases hospital in Albania. 
We conducted a cross sectional study in patients discharged from this 
hospital in Tirana during the period from October 1, 2011 to December 30, 
2011 and their medical files were consulted. The detection of pDDIs among 
prescribed drugs was performed through the Thompson Micromedex®1.0 
program, independently by two pharmacists. 31.4% (56) of all patients 
included in the study experienced at least one pDDI, most of which were of 
moderate severity and well documented. Drugs most frequently involved in 
potential DDIs were NSAIDs (24.5%), fluoroquinolones (22.4%), and 
aminoglycosides (14.3%). Most prevalent specific risks due to pDDIs were 
decreased effectiveness or decreased plasma levels of one of the drugs 
(29.6%), increased response or plasma levels of one of the drugs, with risk of 
increased toxicity (26.5%) and increased risk for tendon rupture (9.1%). 
According to the results of this study, pDDIs in Albania are frequent and 
potentially avoidable. Further divulgation and awareness is needed to prevent 
harmful or clinically important drug-drug interactions. The utilization of 
appropriate computer programs, pharmacotherapeutic monitoring of patients 
and the pharmacist´s presence in the multidisciplinary team are some of the 
recommended ways for the improvement of hospitalized patients´ treatment. 
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Introduction 
 When two drugs are administered to a patient, they may act 
independently, or interact with each other. The interaction may increase or 
decrease the effects of the involved drugs and sometimes may cause 
unexpected toxicity, side effects or failure of the pharmacological therapy 
(Hussar, 2007). As newer and more potent drugs become available, the 
number of serious drug interactions is likely to increase. In a study 
conducted in an emergency department, De Paepe, Petrovic, Outtier, Van 
Maele & Buylaert concluded that clinically relevant interactions were related 
with older age and number of drugs. Measured frequencies of potential drug-
drug interactions (pDDIs) vary considerably in different study settings 
(healthcare levels), ranging from 11% as recorded by Askari et al. in an 
intensive care unit to 27.8% by Zwart-van Rijkom et al. in a Dutch university 
hospital and 63% by Mino-León et al in an internal medicine ward in Mexico 
city. All authors agree that most of the undesired pDDIs are avoidable and 
implementation of appropriate clinical decision support systems such as 
computerized alerts or laboratory monitoring might be helpful to decrease 
pDDIs and potentially enhance patients´ safety. Various studies have showed 
that drug-drug interactions were associated with polypharmacy (taking more 
than five drugs), length of stay and cost of hospitalization (Moura, Acurcio 
& Belo; Vonbach, Dubied, Beer & Krähenbühl). Better knowledge of 
significantly important pDDIs, identification and characterization of all 
factors influencing in pDDIs occurrence is essential to improve prescription 
of medications and therapeutic management of treatments. Since there are no 
previous data available regarding this health issue in our country, a 
structured observational study was performed.  
The objective of this study was to assess the frequency of potential 
drug-drug interactions and characterize them in patients hospitalized in an 
Infectious Diseases hospital in Albania.  
 
Methods 
Study design: Cross sectional study.  
Reference population was patients discharged from the University 
Hospital Center "Mother Teresa" in Tirana during the period from October 1, 
2011 to December 30, 2011.  
The University Hospital Center "Mother Teresa" provides secondary 
hospital services to the Tirana region and at the same time serves as a tertiary 
hospital (about 30% of beds) offering a range of unique specialist services in 
Albania. This Center gives specialized medical assistance; it serves as the 
basis for the formation of medical students, doctors, health personnel and 
also as the basis of scientific research in the health sector (VKM nr. 70, date 
15.02.2001 ―Status of University Hospitals‖). 
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The Documentation Service provided the information for the period 
of study. It included unique number of the medical file, age, gender, dates of 
admission and discharge. We consulted all medical files for this period, 
excluding those with only one or no drugs prescribed. The detection of 
potential drug-drug interactions (pDDIs) among prescribed drugs was 
performed through the Thompson Micromedex®1.0 program.  
All prescribed drugs in each medical file were checked and the 
pDDIs found were recorded by two pharmacists in a blind manner. The 
profile of pDDIs was evaluated as the percentage of files with at least one 
pDDI and the number of pDDIs in these files. Also, for the purposes of this 
study, the drug interactions found were classified in terms of interaction 
severity and literature documentation. Based on the Thompson Micromedex 
program, pDDIs were classified in contraindicated, major, moderate and 
minor, whereas their documentation as excellent, good, fair.  
The drugs involved in pDDIs were divided by pharmacological 
groups to identify which group had a higher frequency of potential 
interaction between drugs. Also, some of them were evaluated in base of 
their predictability, according to the literature, by Katzung (2007) Basic & 
Clinical Pharmacology. 
We employed Microsoft Excel and StatPlus 2009 for data analysis. A 
descriptive analysis of the study population characteristics was performed. 
 
Results 
One hundred seventy-eight patients (44.4% females), mean age 45.5 
+/- 18.4 years (range 0.5-86), were included in the study. Patients received 
an average of 5.7 drugs (95% CI 5.4-6.1) ranging from 2 to 14 drugs during 
their hospital stay. Mean length-of-stay of patients hospitalized in the 
Infectious Diseases Hospital was approximately 6 days. 31.4% (56) of all 
patients included in the study experienced at least one pDDI (Figure 1).  
 
Figure 1. Potential Drug-Drug Interactions identified in the studied hospital files. 
Ninety-eight potential interactions between drugs were found in 56 
medical files, from which there were 70 different single interactions. The 
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mean number of pDDIs in these files was 1.75 (range 1-6), SD 1.19. As 
shown in Figure 2, in the majority of the files (35) only one pDDI was found.  
 
Figure 2. Distribution of pDDIs in medical files 
 
Out of 98 identified pDDIs, most were of moderate and minor 
severity (65.6% and 16.1%, respectively), shown in Figure 3.  
 
Figure 3. Gravity of pDDIs 
 
Contraindicated - the drugs are contraindicated for concurrent use. 
Major - the interaction may be life-threatening and/or require medical 
intervention to minimize or prevent serious adverse effects. 
Moderate - the interaction may result in an exacerbation of the 
patient‘s condition and/or require an alteration in therapy. 
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Minor - the interaction would have limited clinical effects. 
Manifestations may include an increase in the frequency or severity of side 
effects but generally would not require a major alteration in therapy. 
The literature documentation of these potential DDIs was mainly 
good (51.5%) and fair (28.2%), represented in Figure 4. 
 
Figure 4. Documentation of pDDIs 
 
Excellent - controlled studies have clearly established the existence of 
the interaction. 
Good - documentation strongly suggests the interaction exists, but 
well-controlled studies are lacking. 
Fair - available documentation is poor, but pharmacologic 
considerations lead clinicians to suspect the interaction exists; or, 
documentation is good for a pharmacologically similar drug. 
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Figure 5. Number of pDDIs by pharmacological group of the drugs involved 
 
Most frequently involved in potential DDIs were non-steroidal anti-
inflammatory drugs (24.5%), fluoroquinolones (22.4%), and 
aminoglycosides (14.3%). Also, frequent pDDIs were found with ACE-
Inhibitor drugs (11.2%), glucocorticoids (11.2%), calcium containing 
products (11.2%), beta-blockers (10.2%) and anti-diabetics (10.2%).  
Most prevalent specific risks due to DDI were decreased 
effectiveness (efficacy) or decreased plasma levels of one of the drugs 
(29.6%), increased response or plasma levels of one of the drugs, with risk of 
increased toxicity, (26.5%), increased risk for tendon rupture (9.1%), 
neuromuscular weakness (8.1%), increased risk of seizures (7.1%). 
Figure 6 shows the frequency of different potential drug-drug 
interactions (interactions that occurred only in one file are not shown).    
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Figure 6. Frequency of potential Drug-Drug Interactions in medical files 
 
According to the literature, some of the pDDIs are highly predictable 
(ciprofloxacin concurrently with calcium carbonate, doxycycline with 
calcium chloride), some are predictable (metoprolol with naproxen, enalapril 
with naproxen, enalapril with aspirin, atenolol with insulin, alfuzosin with 
bisoprolol, ramipril with ketoprofen), and the others are not predictable or 
not established.  
Highly predictable – the interaction takes place in almost all the 
patients taking the combination. 
Predictable – the interaction takes place in the majority of the patients 
taking the combination.  
Not predictable – the interaction takes place only in some patients 
taking the combination.  
Not established – the data are not sufficient to evaluate the predictability 
of drug interactions.   
 
Conclusion 
It is the first time that a study concerning the profile of drug 
interactions is conducted in Albania; one of the reasons is the insufficient 
information about pDDIs and their management in hospitalized patients. 
According to the results of this study, pDDIs in Albania are frequent and 
potentially avoidable. Further divulgation and awareness is needed to prevent 
harmful or clinically important drug-drug interactions. The utilization of 
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appropriate computer programs, pharmacotherapeutic monitoring of patients 
and the pharmacist´s presence in the multidisciplinary team are some of the 
recommended ways for the improvement of hospitalized patients´ treatment. 
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